<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372449">
  <stage>Registered</stage>
  <submitdate>28/02/2017</submitdate>
  <approvaldate>26/06/2017</approvaldate>
  <actrnumber>ACTRN12617000922370</actrnumber>
  <trial_identification>
    <studytitle>Inflammation and Colchicine use in patients with ESRF undergoing Dialysis</studytitle>
    <scientifictitle>Understanding the Inflammatory mechanisms and effect of Colchicine in patients with End stage renal failure undergoing Dialysis</scientifictitle>
    <utrn>U1111-1193-5813</utrn>
    <trialacronym>ICED</trialacronym>
    <secondaryid>X17-0008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Kidney Disease</healthcondition>
    <healthcondition>Haemodialysis</healthcondition>
    <healthcondition>Inflammation</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Administration of 1mg Colchicine as an initial dose followed by another 0.5mg second dose one hour later. Tablet administration will be performed by healthcare personnel to confirm adherence</interventions>
    <comparator>The control arm will be patients on haemodialysis who have not treated with Colchicine</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Monocyte function which will be assessed by cell culture, ELISA, western blot and PCR results</outcome>
      <timepoint>1 month post randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Neutrophil function - cell culture, ELISA, western blot and PCR results</outcome>
      <timepoint>1 month post randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total microRNA levels using PCR</outcome>
      <timepoint>1 month post randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in inflammatory cytokine levels (IL-1B, IL-6, IL-12, TNF) and CRP by ELISA assays</outcome>
      <timepoint>1 month post randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with end stage renal failure on haemodialysis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to colchicine
Moderate hepatic dysfunction (Alanine Aminotransferase 1.5x upper limit of normal range)
Thrombocytopaenia or leukopaenia
Pregnant or lactating women and women at risk of pregnancy
Patients taking moderate-strong CYP3A4 inhibitors
Patients already taking Colchicine
Those with evidence of active infection of inflammatory conditions that might be associated with markedly elevated CRP levels in the blood and those taking other anti-inflammatory therapies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment will be done at a central administration site</concealment>
    <sequence>Randomisation will be performed using a computerised sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>3/07/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Sanjay Patel</primarysponsorname>
    <primarysponsoraddress>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road, Camperdown 2050
New South Wales</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Heart Research Institute</fundingname>
      <fundingaddress>7 Eliza Street
Newtown 2050
New South Wales</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to look at the inflammatory processes in patients with kidney disease who require haemodialysis. It has been shown that there is a pro-inflammatory process in this cohort of patients and this study intends to look at the specific mechanisms, immune cellular function and inflammatory molecules involved in this process. It also intends to look at the effect of Colchicine, an anti-inflammatory agent on the level of inflammatory molecules </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Local Health District</ethicname>
      <ethicaddress>Research Ethics and Governance Office
Royal Prince Alfred Hospital
Suite 210A, 100 Carillon Ave. Newtown NSW 2042</ethicaddress>
      <ethicapprovaldate>18/05/2017</ethicapprovaldate>
      <hrec>X17-0008</hrec>
      <ethicsubmitdate>15/03/2017</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Sanjay Patel</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050
New South Wales</address>
      <phone>+612 9515 6111 </phone>
      <fax />
      <email>Sanjay.Patel@hri.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rahul Kurup</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050
New South Wales</address>
      <phone>+612 9515 6111 </phone>
      <fax />
      <email>rahulkurup01@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rahul Kurup</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050
New South Wales</address>
      <phone>+612 9515 6111 </phone>
      <fax />
      <email>rahulkurup01@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rahul Kurup</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050</address>
      <phone>+612 9515 6111 </phone>
      <fax />
      <email>rahulkurup01@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>